A New Study Evaluating the Activity of Modular CAR T for mYeloma

This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with relapsed / refractory Multiple Myeloma. The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.

Trial Details

NCT ID
NCT04795882
Phase
PHASE1
Sponsor
University College, London
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • BCMA CAR T cells
  • BCMA/CD19 CAR T cells
Locations (sample)
  • London, County (Optional), United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Relapsed/Refractory Multiple Myeloma
  • Secretory disease: PP≥5g/L and/or sFLC≥100mg/L of involved light chain with abnormal K:L ratio.
  • ≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)
  • Refractory to last line of therapy (not achieved at least PR and progressed within 60 days of last dose or achieved at least PR but progressed with…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →